This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store for how to report side effects. Adverse events should also be reported to MSD on Tel: 01992 467272.

For further information, consult the Patient Information Leaflet (PIL) at www.medicines.org.uk/emc or call MSD Medical Information on Tel: 01992 467272.

**IMPORTANT**
- Do not attempt to diagnose or treat side effects yourself
- Take this card with you at all times, especially when you travel, whenever you go to the Accident and Emergency department, or when you must see another doctor
- Be sure to notify any health care professional you see that you are being treated with pembrolizumab and show them this card
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine
Important Contact Information

Name of Specialist

Phone

After-hours Phone

My Name

My Phone

Emergency Contact (Name)

Emergency Contact (Phone)

Important Information for Health Care Providers

This patient is being treated with KEYTRUDA® (pembrolizumab), which can cause immune-related adverse reactions that involve the lungs, intestines, liver, kidneys, hormone glands, skin, and other organs, as well as infusion-related reactions. Early diagnosis and appropriate management are essential to minimise any consequences of immune-related adverse reactions.

For suspected immune-related adverse reactions, ensure adequate evaluation to confirm aetiology or exclude other causes. Based on the severity of the adverse reaction, withhold pembrolizumab and administer corticosteroids. Specific guidelines for managing immune-related adverse reactions are available in the Summary of Product Characteristics for pembrolizumab.

Consultation with an oncologist or other medical specialist may be helpful for management of organ-specific immune-related adverse reactions.

Assess patients for signs and symptoms of pneumonitis, colitis, hepatitis, nephritis, endocrinopathies, including hypophysitis, type 1 diabetes mellitus (including diabetic ketoacidosis), hypothyroidism, hyperthyroidism and skin adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Other immune-related adverse reactions reported in patients receiving pembrolizumab include: uveitis, arthritis, myositis, myocarditis, pancreatitis, Guillain-Barré syndrome, solid organ transplant rejection following pembrolizumab treatment in donor organ recipients, myasthenic syndrome, haemolytic anaemia, sarcoidosis and encephalitis, as well as complications of allogeneic haematopoietic stem cell transplant.